> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Mull Minimal Residual Disease Endpoint
- URL: https://www.fdaweb.com/panel-to-mull-minimal-residual-disease-endpoint/
- Published: 2024-03-25T12:00:00.000Z
- Updated: 2026-09-14T14:26:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156626

*Federal Register* notice: FDA is announcing a 4/12 Oncologic Drugs Advisory Committee meeting. Panel members are scheduled to discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-06314.pdf?ref=fdaweb.com).